G1 Therapeutics Inc
GTHX
Market Cap$244.29M
Close$
$10.62
160.3% upside
Current Fair Value
160.3% upsideUndervalued by 160.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $244.29 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 2.07 |
| Outstanding Shares | 52,199,394 |
| Avg 30 Day Volume | 877,792 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About G1 Therapeutics Inc
CEO: Mark Velleca